Objective: To characterize features and response to treatment of keratoconjunctivitis sicca (KCS) associated with oral administration of etodolac in dogs.
Design: Retrospective case series.
Sample Population: 65 cases obtained from a survey of veterinary ophthalmologists (group A) and 146 cases reported to Fort Dodge Animal Health (group B).
Procedures: Data analyzed included breed, sex, age, weight, dose and duration of etodolac administration, results of Schirmer tear test at the time of diagnosis and last follow-up, treatments, and response to treatments. Groups A and B were analyzed separately by use of forward stepwise logistic regression models developed to predict probability of complete remission or clinical improvement as a function of several variables.
Results: Most dogs developed severe KCS (84 eyes of 50 dogs [group A]; 111 eyes of 62 dogs [group B]). Resolution of KCS occurred in 7 of 65 (A) and 23 of 146 (B) dogs. No response to treatment was observed in 26 of 65 (A) and 27 of 146 (B) dogs. Fifty-one (A) and 52 (B) dogs had records that were sufficiently complete to use in models. In group B, dogs with etodolac treatment intervals < 6 months prior to the onset of KCS were 4.2 times as likely to have remission as were dogs with treatment intervals > or = 6 months.
Conclusions And Clinical Relevance: Shorter duration of etodolac administration (< 6 months) was associated with improved outcome in 1 population of dogs. Monitoring of tear production should be considered prior to and during administration of etodolac in dogs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2460/javma.230.4.541 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A prospective split-mouth clinical study: comparison of the effect of lornoxicam and etodolac on postoperative sequels following lower third molar surgery.
Oral Maxillofac Surg
November 2024
Department of Oral and Maxillofacial Surgery, Balıkesir Oral and Dental Health Hospital, Balıkesir, Turkey.
Purpose: This study aims to compare the efficacy of two non-steroidal anti-inflammatory agents (NSAIDs), namely lornoxicam and etodolac for controlling pain, edema and trismus after removal of lower impacted third molars.
Materials And Methods: A total of 20 patients comprised of both genders with bilateral impacted lower impacted third molars (in similar positions) was included in the present study. Patients were randomly assigned either to the lornoxicam group (8 mg of lornoxicam) or to the etodolac group (400 mg of etodolac).
Etodolac utility in osteoarthritis: drug delivery challenges, topical nanotherapeutic strategies and potential synergies.
Ther Deliv
November 2024
Department of Pharmaceutics, National Institute of Pharmaceutical Education & Research, Hyderabad, Telangana, India.
Osteoarthritis (OSA) is a prevalent joint disorder characterized by losing articular cartilage, primarily affecting the hip, knee and spine joints. The impact of OSA offers a major challenge to health systems globally. Therapeutic approaches encompass surgical interventions, non-pharmacological therapies (exercise, rehabilitation, behavioral interventions) and pharmacological treatments.
View Article and Find Full Text PDFFollicular mediated etodolac phosalosomal gel for contact dermatitis alleviation, insights from optimization to in-vivo appraisal.
Sci Rep
September 2024
Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, 1 Khartoum Square, Azarita, Post Office, P.O. Box 21521, Alexandria, Egypt.
Article Synopsis
- Etodolac, a cyclooxygenase-2 inhibitor used for inflammatory disorders, struggles with poor water solubility and skin penetration, limiting its clinical effectiveness.
- To address these issues, a new gel combining etodolac with hyaluronic acid in phosalosomes was developed, showing 10.59 times better skin retention and improved tolerability compared to traditional forms.
- In vivo studies indicated that this new gel reduced etodolac accumulation in the liver and kidneys and demonstrated enhanced anti-inflammatory and pain-relieving effects, suggesting it could be useful for targeted treatments of other skin conditions.
Microporation-Mediated Transdermal Delivery of In Situ Gel Incorporating Etodolac-Loaded PLGA Nanoparticles for Management of Rheumatoid Arthritis.
Pharmaceutics
June 2024
Department of Pharmaceutics, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology, 6th of October 12566, Giza, Egypt.
Management of rheumatoid arthritis (RA) requires long-term administration of different medications since there has been no cure until now. Etodolac (ETD) is a nonsteroidal anti-inflammatory drug commonly used for RA management. However, its long-term administration resulted in severe side effects.
View Article and Find Full Text PDFParacetamol Combination Therapy for Back Pain and Osteoarthritis: A Systematic Review and Meta-Analyses.
Drugs
August 2024
Faculty of Medicine and Health, Sydney Musculoskeletal Health, The University of Sydney, Sydney, NSW, Australia.
Background And Objective: Although paracetamol (acetaminophen) combined with other analgesics can reduce pain intensity in some pain conditions, its effectiveness in managing low back pain and osteoarthritis is unclear. This systematic review investigated whether paracetamol combination therapy is more effective and safer than monotherapy or placebo in low back pain and osteoarthritis.
Methods: Online database searches were conducted for randomised trials that evaluated paracetamol combined with another analgesic compared to a placebo or the non-paracetamol ingredient in the combination (monotherapy) in low back pain and osteoarthritis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!